PHARMACOLOGICALLY ACTIVE MODIFIED SB101 MOLECULES AND USES THEREOF

摘要

Modified SB 101 molecules with improved pharmacokinetic characteristics are provided. The pegylated protein has longer half life time than recombinant SB101-Fc fusion protein expressed in mammalian cells. The pegylated SB101 shows more than 70 times longer in vivo plasma half time and the fusion protein shows roughly 10 times longer half life time than unmodified SB101. Pegylated protein and fusion protein have maintained their in vitro activity similar to unmodified SB101. The SB101 fusion protein -molecules inhibit angiogenesis, block endothelial cell response to VEGF and inhibit VEGF receptor 2 protein. The modified molecules with improved pharmacokinetic characters are candidates for treatment of angiogenesis related diseases such as cancer.